Pharmaceuticals

Google-backed AI drug discovery startup Isomorphic Labs is reportedly in early talks to raise funds at a $40 billion to $50 billion valuation, led by Nobel laureate Demis Hassabis.

Early investor Alejandro Weinstein exited Smart Shooter for NIS 58 million following a massive US contract. While scoring big there, his investments in Israeli firms Pluri and Gauzy have faced massive downturns.

Hundreds of patients filed lawsuits against GLP-1 drug makers Novo Nordisk and Eli Lilly, alleging sudden vision loss linked to medications like Ozempic and Mounjaro.

Eli Lilly dominates the booming weight-loss drug market, capturing 60% of the U.S. market share and outperforming rival Novo Nordisk with surging quarterly revenues.

Novo Nordisk aims to launch five new blockbuster drugs by 2030 and reach $23 billion in annual revenue by 2035, facing rising competition from Eli Lilly and generic alternatives.

Good news for consumers: the supermarket chain is launching "Pharm Express" stands and offering 24 types of over-the-counter medications in 32 of its branches. Among the products: Advil, Acamol, Nurofen, and Fenistil.

Teva reported positive results in a clinical trial for the treatment of celiac disease. The trial met its primary endpoint, demonstrating that the TEV-408 antibody prevents intestinal damage.

The company reports success in a clinical trial for a drug that blocks an inflammatory protein. The treatment is intended for two different conditions and is expected to advance to later development stages soon.

Biomedical company BioXcel has filed for bankruptcy protection. Pharma giant Teva is serving as the stalking horse bidder in the auction, on the way to a potential acquisition of revolutionary AI-based drugs.

The Turkish Competition Authority has opened an investigation into the pharmaceutical company Teva on suspicion of taking steps to limit competition in the generic drug market, including through the strategic use of patent procedures and the presentation of allegedly misleading information to health authorities. The company stated: "This is a process concerning the Copaxone drug from the past, and...

While Moderna grabbed headlines with a 177% jump, its partner Merck recorded its best day since 2009. Morgan Stanley has upgraded its recommendation, highlighting the company's potential beyond its flagship drug, despite the looming patent expiration.

The company, traded on NASDAQ and focused on urinary tract cancer treatments, has announced a collaboration agreement with the Israeli firm Intragel, which has developed a biodegradable gel for the sustained release of drugs.

The FDA has accepted for review Teva's application for the approval of Aukopipam for the treatment of children with Tourette syndrome and has granted it an accelerated pathway. If approved, it could be the first drug in the field with a new mechanism of action in over 50 years.

After a prolonged period of stagnation, one of the continent's strongest economies is presenting exceptional growth figures that beat forecasts. What is the surprising factor that led to the radical trend shift and how are the USA connected to the story?

With revenues of over $100 million in the first half of the year and a sharp jump in net profit, the Israeli company reports unprecedented results and marks its next target.

The company that developed a non-hormonal drug for treating hot flashes. The financial institution that began covering the biomed market. What remains of the cannabis company Tikun Olam. And the success of Israel's UroGen with a cancer treatment product. This week in biomed.

The pharmaceutical company CTS is being sold to Dexcel Pharma for approximately 250 million shekels. The acquisition covers only the pharmaceutical operations, while other business units remain separate.

Three years ago, Novo Nordisk ruled the market with an iron hand, but Eli Lilly has made a massive overtake. The pill revolution, price drops in the USA, and a lawsuit — the drama behind a market worth hundreds of billions.

Developing a new drug is one of the most time-consuming and expensive processes in medicine. Despite billions in investment, many drugs fail during clinical trials. The Israeli startup QuantHealth has secured $45 million to expand its artificial intelligence platform, which aims to optimize the planning and execution of clinical trials.

After recording an impressive jump in profits above forecasts, the company is preparing for a dramatic change and is signaling a mega-acquisition to enter one of the most profitable markets in the pharma world with force.

Employees of the pharmaceutical manufacturer Rafa are on strike, demanding bonuses for their role in the company's IPO and value growth. Workers have rejected management's offer of a one-time 2,000 shekel payment.

Reports indicate that pharmaceutical giants AstraZeneca and Bristol-Myers Squibb (BMS) are in talks regarding a potential merger. If successful, the deal could create a combined entity with a market capitalization of nearly $400 billion, marking one of the largest transactions in industry history.

Teva's transformation from a generics manufacturer to an originator drug developer has pushed its market cap above $40 billion. The company is planning a direct listing in New York to facilitate its inclusion in the S&P 500 index.

Teva reported $4.1 billion in revenue, exceeding analyst forecasts. Net profit was 2 cents per share versus the expected 11 cents, due to Emalex acquisition costs. The company raised its annual revenue guidance, and shares are up over 4% in Tel Aviv.

The fundraising, more than double the company's market value on the eve of the announcement, is expected to fund its operations until 2030. Among the Israeli connections: cooperation with Opko and a holding by Canada Israel Hotels.

Logistics giants UPS and FedEx are investing millions in refrigerated facility upgrades to accommodate the transport of weight-loss drugs like Wegovy and Ozempic.